Weiss Law investigates Checkmate Pharmaceuticals, Inc.

NEW YORK , April 19, 2022 /PRNewswire/ — Weiss’ law investigation of possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate Pharmaceuticals, Inc. (“Checkmate” or the “Company”) (NASDAQ: CMPI), as part of the proposed acquisition of the Company by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), via a public tender offer. Under the terms of the merger agreement, shareholders of the Company will receive $10.50 in cash for each common share of Checkmate held. The transaction is valued at $250 million.

If you own Checkmate actions and wish to discuss this survey or have questions about this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/cmpi
Or please contact:
Joshua Rubin, Esq.
Weiss’ law
305 Broadway, 7and Stage
New YorkNY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) Checkmate’s board of directors acted in the best interests of the company’s shareholders in agreeing to the proposed transaction, (ii) the $10.50 the merger consideration per share adequately compensates Checkmate shareholders, and (iii) all information regarding the sale process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of shareholder class and derivative actions for breach of corporate and fiduciary duties. We’ve recovered over $1 billion for defrauded customers and won significant corporate governance relief in many of those cases. If you have information or want legal advice regarding possible corporate wrongdoing (including insider trading, waste of company assets, accounting fraud or misleading information), fraud consumer rights (including false advertising, defective products or other deceptive marketing practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss’ Law

Comments are closed.